Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
adults (for DLBCL)
patients up to 25 years old (for ALL) |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL03
|
| gptkbp:blackBoxWarning |
yes
|
| gptkbp:brand |
gptkb:Kymriah
|
| gptkbp:CASNumber |
1702807-28-7
|
| gptkbp:cost |
high
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:firstBook |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
tisagenlecleucel
|
| gptkbp:indication |
diffuse large B-cell lymphoma
B-cell acute lymphoblastic leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells
targets CD19 antigen |
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities infection risk |
| gptkbp:source |
autologous T cells
|
| gptkbp:storage |
cryopreserved
|
| gptkbp:UNII |
6H4G3K4Q1S
|
| gptkbp:bfsParent |
gptkb:Kymriah
|
| gptkbp:bfsLayer |
5
|